Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study - Wikidata - wikimedia - TriplyDB

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

http://www.wikidata.org/entity/Q58618185

about

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

http://www.wikidata.org/entity/Q58618185

description

article publié dans la revue scientifique Scientific Reports

@fr

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in Scientific Reports

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@en

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@nl

type

label

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@en

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@nl

prefLabel

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@en

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@nl

P1433

Q58618185-6BF25A9F-1F7F-48A8-99A2-3E846DD4E5A2

P1476

Q58618185-865532D4-FD76-4656-AEA4-46F0B53D5DEB

P2093

Q58618185-2FF9AC55-7D00-494C-807F-A597D33AB412

Q58618185-3C767C72-4813-480A-88EF-B1E50419C64A

Q58618185-83C7744F-BCC5-4129-9271-5AD6E2D3343F

Q58618185-9886D41E-7F96-4E40-91C8-5534707DE9CF

Q58618185-A1482314-0C60-48DB-BF24-659202998F52

Q58618185-B7AADF31-45DA-49AC-ACFD-A39C1E1331DC

Q58618185-C037D0A5-D17D-459D-9E82-94288003EB9E

Q58618185-C90B5AB3-69A7-4321-AD29-63E7E56993E5

Q58618185-C944E4B6-40BE-49D1-AEA8-42D3F5C153EB

Q58618185-DCCBEA2C-2DB4-4664-9DFD-67F82BACA3D4

P2860

Q58618185-03863277-E9D4-458D-BED3-14B2B0225F54

Q58618185-05E17AF7-F81D-489B-B0FF-6A85CA68855C

Q58618185-140C2E35-C931-47A9-B44F-0FC481E96079

Q58618185-2EF41F79-A306-4888-80E0-6B06AA92B27A

Q58618185-3D771C3B-8182-449E-9555-35296233E7E6

Q58618185-527B0F3F-BB07-4EC1-B710-34BAB0E7405C

Q58618185-5A641E62-2AA2-402A-A115-C9F69143D74D

Q58618185-5C859260-1AFA-4854-9203-B953520DD5E2

Q58618185-5FC683CE-319A-45D7-84C1-4B68C577FA7C

Q58618185-610CD865-50D4-4FF0-8D9E-1A17FCEB48DA

P304

Q58618185-AD1FE7E8-8214-4F7F-92FC-68E035C8DC45

P31

Q58618185-63B72E9D-7C54-4D20-B103-17FE9E881751

P356

Q58618185-0690D352-396D-4DFA-8B9B-BC4B7ADB14EF

P407

Q58618185-446F29A4-C412-4162-8BF0-52DDBF92BFFA

P433

Q58618185-F64449EC-F3B5-4E0B-B898-2681B72E1C3D

P478

Q58618185-468EE199-0444-466F-8EF9-507A49E519ED

P577

Q58618185-1D9592D9-CEBC-4261-8173-913F14235221

P698

Q58618185-A5C536F8-9CAF-443A-8DBA-98CDD292F177

P921

Q58618185-BAF86335-FBEE-4323-981F-82ADD04C8176

P932

Q58618185-E60B3C3A-BC55-4D0D-8AE6-A95658C0F10A

P356

S41598-018-34618-X

P1433

Scientific Reports

P1476

Olanzapine plus aprepitant, pa ...... cycline: A retrospective study

@en

P2093

Akari Murakami

http://www.w3.org/2001/XMLSchema#string

Erina Kusakabe

http://www.w3.org/2001/XMLSchema#string

Haruna Yamasawa

http://www.w3.org/2001/XMLSchema#string

Hitoshi Kawazoe

http://www.w3.org/2001/XMLSchema#string

Kana Kobayashi-Taguchi

http://www.w3.org/2001/XMLSchema#string

Michiko Yamashita

http://www.w3.org/2001/XMLSchema#string

Ryuji Uozumi

http://www.w3.org/2001/XMLSchema#string

Tomonori Nakamura

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Kamei

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Yakushijin

http://www.w3.org/2001/XMLSchema#string

P2860

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.

The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor.

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

P304

16232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-34618-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30389996

http://www.w3.org/2001/XMLSchema#string

P921

P932

6214966

http://www.w3.org/2001/XMLSchema#string